Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 2, pp. 95-102
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Andrés Chang, Akil Akhtar, Susanne L. Linderman, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3020-3031
Open Access | Times Cited: 40
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
RNA vaccines for cancer: Principles to practice
Pablo Guasp, Charlotte Reiche, Zachary Sethna, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1163-1184
Closed Access | Times Cited: 10
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 31
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination
Jon Riise, Saskia Meyer, Isaac Blaas, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 6, pp. 697-708
Open Access | Times Cited: 30
Effect of immunomodulatory agents on the response to COVID-19 vaccination among patients with neuromuscular diseases: A single center experience
J.J. Hsu, Perry B. Shieh
Medicine (2025) Vol. 104, Iss. 9, pp. e41606-e41606
Open Access
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
Sophia Ly, Dmitry A. Nedosekin, Henry K. Wong
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 2, pp. 247-273
Open Access | Times Cited: 12
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 6, pp. 481-489
Open Access | Times Cited: 21
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Samuel M. Rubinstein, Divaya Bhutani, Ryan C. Lynch, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 3, pp. 181-193
Open Access | Times Cited: 14
Management of vaccinations in patients with non‐Hodgkin lymphoma
Michele Merli, Andrea Costantini, Silvio Tafuri, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1617-1634
Open Access | Times Cited: 2
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study
Tobias Moser, Ferdinand Otto, Ciara K. O’Sullivan, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103560-103560
Open Access | Times Cited: 13
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
Mazyar Shadman, Catherine Liu, Katherine Eakle, et al.
HemaSphere (2022) Vol. 7, Iss. 1, pp. e811-e811
Open Access | Times Cited: 12
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
Ann Tivey, Rohan Shotton, Toby A. Eyre, et al.
Blood Advances (2023) Vol. 8, Iss. 5, pp. 1209-1219
Open Access | Times Cited: 7
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
Akio Onishi, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 509-519
Open Access | Times Cited: 6
Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves
Zachary M. Avigan, Rodrigo Paredes, Leora Boussi, et al.
Cancer Medicine (2023) Vol. 12, Iss. 16, pp. 16869-16875
Open Access | Times Cited: 5
Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
Kirsten S. Evonuk, Sen Wang, Josh Mattie, et al.
Acta Neuropathologica Communications (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 5
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study
Martin Schönlein, Victoria Wrage, Susanne Ghandili, et al.
Cancer Cell (2022) Vol. 40, Iss. 6, pp. 581-583
Open Access | Times Cited: 9
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
Tobias Moser, Ciara K. O’Sullivan, Ferdinand Otto, et al.
Therapeutic Advances in Neurological Disorders (2022) Vol. 15, pp. 175628642210920-175628642210920
Open Access | Times Cited: 9
SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis
Raquel Valdes Angues, Yolanda Perea Bustos
Cureus (2023)
Open Access | Times Cited: 4
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy
Joseph Azar, John P. Evans, Madison H. Sikorski, et al.
JCI Insight (2023) Vol. 8, Iss. 6
Open Access | Times Cited: 3
Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
Odit Gutwein, Katrin Herzog Tzarfati, Arie Apel, et al.
Cancer Medicine (2023) Vol. 12, Iss. 21, pp. 20503-20510
Open Access | Times Cited: 3
Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity
Katie E. Lineburg, Pauline Crooks, Jyothy Raju, et al.
iScience (2023) Vol. 26, Iss. 12, pp. 108474-108474
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top